Hemostemix Inc. (HEM.V)
CAD 0.1
(26.67%)
CAD 0.1
(26.67%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 7.68 Million CAD | 6.23% |
| 2022 | 7.23 Million CAD | 23.73% |
| 2021 | 5.84 Million CAD | 70.87% |
| 2020 | 3.42 Million CAD | -17.54% |
| 2019 | 4.14 Million CAD | 253.31% |
| 2018 | 1.17 Million CAD | 152.68% |
| 2017 | 464.79 Thousand CAD | -87.4% |
| 2016 | 3.68 Million CAD | 492.45% |
| 2015 | 622.72 Thousand CAD | 12.87% |
| 2014 | 551.7 Thousand CAD | 127.05% |
| 2013 | 242.98 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 8.6 Million CAD | 8.37% |
| 2024 Q1 | 7.93 Million CAD | 3.28% |
| 2023 FY | 7.68 Million CAD | 6.23% |
| 2023 Q2 | 7.18 Million CAD | -3.93% |
| 2023 Q1 | 7.48 Million CAD | 3.46% |
| 2023 Q4 | 7.68 Million CAD | 1.74% |
| 2023 Q3 | 7.55 Million CAD | 5.06% |
| 2022 Q1 | 6.86 Million CAD | 17.37% |
| 2022 FY | 7.23 Million CAD | 23.73% |
| 2022 Q2 | 5.38 Million CAD | -21.59% |
| 2022 Q3 | 5.08 Million CAD | -5.46% |
| 2022 Q4 | 7.23 Million CAD | 42.2% |
| 2021 Q3 | 4.61 Million CAD | 1.15% |
| 2021 Q1 | 2.48 Million CAD | -27.36% |
| 2021 Q2 | 4.56 Million CAD | 83.6% |
| 2021 FY | 5.84 Million CAD | 70.87% |
| 2021 Q4 | 5.84 Million CAD | 26.66% |
| 2020 Q2 | 3.24 Million CAD | 20.68% |
| 2020 Q3 | 4.26 Million CAD | 31.39% |
| 2020 Q4 | 3.42 Million CAD | -19.82% |
| 2020 Q1 | 2.69 Million CAD | -35.13% |
| 2020 FY | 3.42 Million CAD | -17.54% |
| 2019 Q4 | 4.14 Million CAD | 26.6% |
| 2019 FY | 4.14 Million CAD | 253.31% |
| 2019 Q3 | 3.27 Million CAD | 78.85% |
| 2019 Q2 | 1.83 Million CAD | 35.98% |
| 2019 Q1 | 1.34 Million CAD | 14.75% |
| 2018 FY | 1.17 Million CAD | 152.68% |
| 2018 Q4 | 1.17 Million CAD | 46.91% |
| 2018 Q3 | 799.45 Thousand CAD | -5.26% |
| 2018 Q2 | 843.81 Thousand CAD | -2.65% |
| 2018 Q1 | 866.81 Thousand CAD | 86.49% |
| 2017 Q1 | 3.21 Million CAD | -12.74% |
| 2017 Q2 | 3.58 Million CAD | 11.45% |
| 2017 Q3 | 486.64 Thousand CAD | -86.44% |
| 2017 Q4 | 464.79 Thousand CAD | -4.49% |
| 2017 FY | 464.79 Thousand CAD | -87.4% |
| 2016 Q4 | 3.68 Million CAD | 42.99% |
| 2016 FY | 3.68 Million CAD | 492.45% |
| 2016 Q1 | 861.74 Thousand CAD | 38.38% |
| 2016 Q2 | 1.46 Million CAD | 70.53% |
| 2016 Q3 | 2.58 Million CAD | 75.58% |
| 2015 Q1 | 496.54 Thousand CAD | -10.0% |
| 2015 Q4 | 622.72 Thousand CAD | 20.23% |
| 2015 Q3 | 517.94 Thousand CAD | -13.03% |
| 2015 Q2 | 595.56 Thousand CAD | 19.94% |
| 2015 FY | 622.72 Thousand CAD | 12.87% |
| 2014 Q2 | 71.75 Thousand CAD | 617.51% |
| 2014 Q1 | 10 Thousand CAD | -53.69% |
| 2014 FY | 551.7 Thousand CAD | 127.05% |
| 2014 Q4 | 551.7 Thousand CAD | 2582.08% |
| 2014 Q3 | 20.57 Thousand CAD | -71.33% |
| 2013 FY | 242.98 Thousand CAD | 0.0% |
| 2013 Q2 | 30.38 Thousand CAD | 176.33% |
| 2013 Q3 | 23.51 Thousand CAD | -22.6% |
| 2013 Q4 | 21.59 Thousand CAD | -8.17% |
| 2013 Q1 | 10.99 Thousand CAD | -50.11% |
| 2012 Q4 | 22.03 Thousand CAD | -15.24% |
| 2012 Q3 | 26 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Arch Biopartners Inc. | 6.68 Million CAD | -15.028% |
| Covalon Technologies Ltd. | 6.1 Million CAD | -25.823% |
| Universal Ibogaine Inc. | 2.37 Million CAD | -223.624% |
| Kane Biotech Inc. | 14.09 Million CAD | 45.459% |
| MedMira Inc. | 18.68 Million CAD | 58.867% |
| Marvel Biosciences Corp. | 2.39 Million CAD | -221.215% |
| NervGen Pharma Corp. | 15.24 Million CAD | 49.59% |
| XORTX Therapeutics Inc. | 1.08 Million CAD | -605.64% |